BioAge Labs Inc. BIOA 深 滬
等待開盤 08-04 09:30:00 美东时间
4.12
-0.280
-6.36%
華盛通- 最 高4.43
- 今 開4.36
- 成交量 32.41万股
- 最 低 4.11
- 昨 收 4.40
- 總市值 1.48亿
- 52周最高 26.62
- 市盈率 靜 --
- 換手率 0.90%
- 52周最低 0.156
- 委 比 81.56%
- 總股本 3585.00万
- 歷史最高 26.62
- 量 比 4.16
- 振 幅 7.27%
- 歷史最低 0.156
- 每 手 1
- 風險率 7.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioArctic and Eisai to Present Lecanemab Data at AAIC 2025
An announcement from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available. Bi...
07-22 14:33
BioArctic’s Alzheimer’s Drug Lecanemab Wins Prestigious Bioindustry Award
BioArctic AB Class B ( ($SE:BIOA.B) ) has issued an update. BioArctic AB’s part...
07-16 16:02
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
BioAtla's BA3182, a dual-CAB EpCAM x CD3 bispecific T-cell engager, showed preliminary success in phase 1 trials for heavily pretreated metastatic adenocarcinoma patients. Safety profile was favorable with low-grade, transient adverse events. Tumor reductions were observed, and dose escalation continues at 1.2 mg weekly. Phase 1 data updates are expected in 2H2025.
07-03 12:00
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
BioCryst Pharmaceuticals has agreed to sell its European ORLADEYO business to Neopharmed Gentili for up to $264 million. The deal includes a $250 million upfront payment and up to $14 million in future milestones. BioCryst plans to use the proceeds to repay $249 million in debt, eliminating $70 million in future interest payments. The company expects to end 2027 with $700 million in cash and no term debt, a $400 million increase from prior guidan...
06-27 11:00
BioArctic Founder Awarded Prestigious Prize for Alzheimer’s Research
The latest update is out from BioArctic AB Class B ( ($SE:BIOA.B) ). BioArctic ...
06-26 16:33
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
A study presented by BioAge Labs highlights the potential of apelin receptor (APJ) agonists in improving glycemic control and offering cardioprotective benefits in models of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The research indicates that APJ agonists can enhance the effects of incretin therapies, potentially leading to better outcomes for patients with type 2 diabetes and obesity-related heart failure. Bio...
06-21 22:00
BioAge Labs To Profile 17,000+ HUNT Biobank Samples In Norway To Accelerate Aging-Related Drug Target Discovery
Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseasesNew data deepen platform insights into the
06-17 21:07
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
BioAge Labs collaborates with Age Labs AS to analyze over 17,000 samples from the HUNT Biobank in Norway, aiming to accelerate the discovery of drug targets for aging-related diseases. Using advanced proteomic tools and machine learning, the partnership will generate insights into resilience across multiple health conditions, enhancing BioAge’s discovery platform for novel therapeutic targets.
06-17 13:00
BioArctic Advances Exidavnemab Study Following Positive Safety Review
BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an update. BioArctic AB ann...
06-13 14:32
ORLADEYO® (berotralstat) Approved in Colombia
BioCryst Pharmaceuticals宣布，哥伦比亚国家药物和食品监管局（INVIMA）已批准口服药物ORLADEYO®（berotralstat）作为预防12岁及以上遗传性血管性水肿（HAE）患者的治疗方法。BioCryst与Pint Pharma合作在拉美地区推广该药，此前已在智利、阿根廷、巴西、墨西哥和秘鲁获得批准。ORLADEYO为首个针对HAE的口服每日一次预防药物，可通过抑制血浆激肽释放酶减少发作。常见副作用包括腹痛、呕吐和腹泻，需注意药物相互作用及肝功能受损患者的剂量调整。该药正在多个拉美市场推广，BioCryst致力于为患者提供新的治疗选择。
06-13 11:00
